Cargando…

The antisecretory peptide AF-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis

Sepsis is a life-threatening condition due to a dysregulated immunological response to infection. Apart from source control and broad-spectrum antibiotics, management is based on fluid resuscitation and vasoactive drugs. Fluid resuscitation implicates the risk of volume overload, which in turn is as...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrueta Tenhunen, Annelie, van der Heijden, Jaap, Blokhin, Ivan, Massaro, Fabrizia, Hansson, Hans Arne, Feinstein, Ricardo, Larsson, Anders, Tenhunen, Jyrki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446908/
https://www.ncbi.nlm.nih.gov/pubmed/32822373
http://dx.doi.org/10.1371/journal.pone.0232302
_version_ 1783574213912690688
author Barrueta Tenhunen, Annelie
van der Heijden, Jaap
Blokhin, Ivan
Massaro, Fabrizia
Hansson, Hans Arne
Feinstein, Ricardo
Larsson, Anders
Larsson, Anders
Tenhunen, Jyrki
author_facet Barrueta Tenhunen, Annelie
van der Heijden, Jaap
Blokhin, Ivan
Massaro, Fabrizia
Hansson, Hans Arne
Feinstein, Ricardo
Larsson, Anders
Larsson, Anders
Tenhunen, Jyrki
author_sort Barrueta Tenhunen, Annelie
collection PubMed
description Sepsis is a life-threatening condition due to a dysregulated immunological response to infection. Apart from source control and broad-spectrum antibiotics, management is based on fluid resuscitation and vasoactive drugs. Fluid resuscitation implicates the risk of volume overload, which in turn is associated with longer stay in intensive care, prolonged use of mechanical ventilation and increased mortality. Antisecretory factor (AF), an endogenous protein, is detectable in most tissues and in plasma. The biologically active site of the protein is located in an 8-peptide sequence, contained in a synthetic 16-peptide fragment, named AF-16. The protein as well as the peptide AF-16 has multiple modulatory effects on abnormal fluid transport and edema formation/resolution as well as in a variety of inflammatory conditions. Apart from its’ anti-secretory and anti-inflammatory characteristics, AF is an inhibitor of capillary leakage in intestine. It is not known whether the protein AF or the peptide AF-16 can ameliorate symptoms in sepsis. We hypothesized that AF-16 decreases the degree of hemodynamic instability, the need of fluid resuscitation, vasopressor dose and tissue edema in fecal peritonitis. To test the hypothesis, we induced peritonitis and sepsis by injecting autologous fecal solution into abdominal cavity of anesthetized pigs, and randomized (in a blind manner) the animals to intervention (AF-16, n = 8) or control (saline, n = 8) group. After the onset of hemodynamic instability (defined as mean arterial pressure < 60 mmHg maintained for > 5 minutes), intervention with AF-16 (20 mg/kg (50 mg/ml) in 0.9% saline) intravenously (only the vehicle in the control group) and a protocolized resuscitation was started. We recorded respiratory and hemodynamic parameters hourly for twenty hours or until the animal died and collected post mortem tissue samples at the end of the experiment. No differences between the groups were observed regarding hemodynamics, overall fluid balance, lung mechanics, gas exchange or histology. However, liver wet-to-dry ratio remained lower in AF-16 treated animals as compared to controls, 3.1 ± 0.4, (2.7–3.5, 95% CI, n = 8) vs 4.0 ± 0.6 (3.4–4.5, 95% CI, n = 8), p = 0.006, respectively. Bearing in mind the limited sample size, this experimental pilot study suggests that AF-16 may inhibit sepsis induced liver edema in peritonitis-sepsis.
format Online
Article
Text
id pubmed-7446908
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-74469082020-08-26 The antisecretory peptide AF-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis Barrueta Tenhunen, Annelie van der Heijden, Jaap Blokhin, Ivan Massaro, Fabrizia Hansson, Hans Arne Feinstein, Ricardo Larsson, Anders Larsson, Anders Tenhunen, Jyrki PLoS One Research Article Sepsis is a life-threatening condition due to a dysregulated immunological response to infection. Apart from source control and broad-spectrum antibiotics, management is based on fluid resuscitation and vasoactive drugs. Fluid resuscitation implicates the risk of volume overload, which in turn is associated with longer stay in intensive care, prolonged use of mechanical ventilation and increased mortality. Antisecretory factor (AF), an endogenous protein, is detectable in most tissues and in plasma. The biologically active site of the protein is located in an 8-peptide sequence, contained in a synthetic 16-peptide fragment, named AF-16. The protein as well as the peptide AF-16 has multiple modulatory effects on abnormal fluid transport and edema formation/resolution as well as in a variety of inflammatory conditions. Apart from its’ anti-secretory and anti-inflammatory characteristics, AF is an inhibitor of capillary leakage in intestine. It is not known whether the protein AF or the peptide AF-16 can ameliorate symptoms in sepsis. We hypothesized that AF-16 decreases the degree of hemodynamic instability, the need of fluid resuscitation, vasopressor dose and tissue edema in fecal peritonitis. To test the hypothesis, we induced peritonitis and sepsis by injecting autologous fecal solution into abdominal cavity of anesthetized pigs, and randomized (in a blind manner) the animals to intervention (AF-16, n = 8) or control (saline, n = 8) group. After the onset of hemodynamic instability (defined as mean arterial pressure < 60 mmHg maintained for > 5 minutes), intervention with AF-16 (20 mg/kg (50 mg/ml) in 0.9% saline) intravenously (only the vehicle in the control group) and a protocolized resuscitation was started. We recorded respiratory and hemodynamic parameters hourly for twenty hours or until the animal died and collected post mortem tissue samples at the end of the experiment. No differences between the groups were observed regarding hemodynamics, overall fluid balance, lung mechanics, gas exchange or histology. However, liver wet-to-dry ratio remained lower in AF-16 treated animals as compared to controls, 3.1 ± 0.4, (2.7–3.5, 95% CI, n = 8) vs 4.0 ± 0.6 (3.4–4.5, 95% CI, n = 8), p = 0.006, respectively. Bearing in mind the limited sample size, this experimental pilot study suggests that AF-16 may inhibit sepsis induced liver edema in peritonitis-sepsis. Public Library of Science 2020-08-21 /pmc/articles/PMC7446908/ /pubmed/32822373 http://dx.doi.org/10.1371/journal.pone.0232302 Text en © 2020 Barrueta Tenhunen et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Barrueta Tenhunen, Annelie
van der Heijden, Jaap
Blokhin, Ivan
Massaro, Fabrizia
Hansson, Hans Arne
Feinstein, Ricardo
Larsson, Anders
Larsson, Anders
Tenhunen, Jyrki
The antisecretory peptide AF-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis
title The antisecretory peptide AF-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis
title_full The antisecretory peptide AF-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis
title_fullStr The antisecretory peptide AF-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis
title_full_unstemmed The antisecretory peptide AF-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis
title_short The antisecretory peptide AF-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis
title_sort antisecretory peptide af-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446908/
https://www.ncbi.nlm.nih.gov/pubmed/32822373
http://dx.doi.org/10.1371/journal.pone.0232302
work_keys_str_mv AT barruetatenhunenannelie theantisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT vanderheijdenjaap theantisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT blokhinivan theantisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT massarofabrizia theantisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT hanssonhansarne theantisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT feinsteinricardo theantisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT larssonanders theantisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT larssonanders theantisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT tenhunenjyrki theantisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT barruetatenhunenannelie antisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT vanderheijdenjaap antisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT blokhinivan antisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT massarofabrizia antisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT hanssonhansarne antisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT feinsteinricardo antisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT larssonanders antisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT larssonanders antisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis
AT tenhunenjyrki antisecretorypeptideaf16maymodulatetissueedemabutnotinflammationinexperimentalperitonitisinducedsepsis